Who
Jonathan Violin
Director
Company insider
Files Form 4 as: Director, Crescent Biopharma; Director, Dianthus Therapeutics; Director, Astria Therapeutics; Chief Executive Officer, Viridian Therapeutics; SVP-Scientific Affairs & IR, Trevena.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $6.1M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 28 Feb 2018
- Last trade
- 2 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 3 Jun 2026 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,050 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,050 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,090 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,090 at $0.00 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria TherapeuticsBiotechnology | SEC FORM 4 Code D | —263,321 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,166 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,333 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,166 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —8,333 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,550 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —26,550 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeutics | SEC FORM 4 Code D | —263,321 | filing |
| 23 Jun 2025filed 23 Jun 2025 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,023 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code A | —26,550 at $0.00 | filing |
| 22 May 2025filed 22 May 2025 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code A | —14,100 at $0.00 | filing |
News
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 7.8% – Here's WhyVRDN · dailypolitical.com · 19 Oct 2026Critical Survey: Emergent Biosolutions (NYSE:EBS) & Viridian Therapeutics (NASDAQ:VRDN)VRDN · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Jonathan Violin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.